-transparent.png){kind=logo}
A phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (amsacrine, m-AMSA) was carried out in previously treated patients with advanced ovarian carcinoma. The dose of amsacrine was 90 mg/m2 every 3 weeks in 34 patients having received prior extensive chemotherapy and/or radiotherapy, and 120 mg/m2 in 5 patients who had previously only received moderate amounts of chemotherapy. Among patients evaluable for response the median number of courses was 3 (range 2-17). Two patients (5%) experienced complete response for 15+ months. Leucopenia was the most frequent toxic effect. WBC nadir was 2700/mm3 (range 1000-7300). Other toxic effects were of lesser significance and included thrombocytopenia, anemia, nausea and vomiting. It is concluded that amsacrine has only marginal activity in patients with previously treated ovarian carcinoma.
P Dombernowsky, and
P Siegenthaler, and
R Somers, and
H H Hansen
May 1983,
Cancer treatment reports,
P Dombernowsky, and
P Siegenthaler, and
R Somers, and
H H Hansen
April 1983,
Cancer treatment reports,
P Dombernowsky, and
P Siegenthaler, and
R Somers, and
H H Hansen
August 1984,
American journal of clinical oncology,
P Dombernowsky, and
P Siegenthaler, and
R Somers, and
H H Hansen
May 1982,
The Australian & New Zealand journal of obstetrics & gynaecology,
P Dombernowsky, and
P Siegenthaler, and
R Somers, and
H H Hansen
June 1982,
American journal of clinical oncology,
P Dombernowsky, and
P Siegenthaler, and
R Somers, and
H H Hansen
August 1982,
Cancer treatment reports,
P Dombernowsky, and
P Siegenthaler, and
R Somers, and
H H Hansen
November 1982,
Cancer treatment reports,
P Dombernowsky, and
P Siegenthaler, and
R Somers, and
H H Hansen
May 1982,
Cancer treatment reports,
P Dombernowsky, and
P Siegenthaler, and
R Somers, and
H H Hansen
June 1980,
Cancer treatment reviews,
P Dombernowsky, and
P Siegenthaler, and
R Somers, and
H H Hansen
October 1988,
American journal of clinical oncology,
